Heart Disease Genetics: Little-Known Chaperone Hero11 Emerges as Coronary Risk Gene

Coronary artery disease remains the single largest cause of death worldwide, and despite decades of research into cholesterol, blood pressure, and inflammation, a substantial share of individual risk remains unexplained by the usual suspects. Now a team of Russian researchers has turned the spotlight on one of the most unexpected candidates yet: a member of a recently discovered family of proteins so obscure that scientists literally named them heat-resistant obscure proteins, or Hero proteins. In a study published in Molecular Biology Reports, Vladislav Shilenok, Ksenia Kobzeva, and Olga Bushueva of Kursk State Medical University report that genetic variants in C19orf53, also known as Hero11, are associated with susceptibility to coronary artery disease and with measurable changes in blood coagulation, the process that turns arterial plaques into potentially fatal clots.

The Hero proteins first came to wide scientific attention in 2020, when researchers in Japan described a widespread family of intrinsically disordered proteins that survive boiling and other harsh treatments that destroy most proteins. Despite lacking the stable three-dimensional folds that traditionally define functional proteins, Hero proteins act as chaperones, molecules that help other proteins maintain their proper shapes and avoid clumping together into toxic aggregates. Protein misfolding and aggregation are best known from neurodegenerative diseases such as Alzheimer’s and amyotrophic lateral sclerosis, but a growing body of evidence suggests they also play a role in the heart and blood vessels. Myocardial infarction has been shown to elevate endoplasmic reticulum stress and protein aggregation in heart tissue, and the RNA-binding protein TDP-43, a famous culprit in motor neuron disease, has been implicated in worsening atherosclerosis by promoting inflammation and lipid uptake in macrophages, the immune cells that populate arterial plaques.

Hero11 attracted particular interest because it has been shown to suppress the aggregation of TDP-43, and independent CRISPR screening work has identified C19orf53 as a gene required for cell proliferation through its connection to mTORC1, a central signaling complex that integrates nutrient and stress signals and is itself deeply entwined with obesity, metabolism, and plaque biology. That combination of chaperone activity, TDP-43 suppression, and mTORC1 involvement made C19orf53 a plausible, if speculative, player in cardiovascular disease. The Kursk team set out to test whether common genetic variation in the gene actually tracks with coronary artery disease in a human population.

To do so, the researchers genotyped seven single-nucleotide polymorphisms, SNPs, in C19orf53 in 2,164 unrelated individuals of Russian ethnicity from Central Russia. The cohort included 836 patients with established coronary artery disease and 1,328 healthy controls. They assessed associations with disease risk and clinical traits using regression analyses corrected for multiple testing by permutation, a statistical resampling approach that guards against false positives, and then used bioinformatic resources to annotate the variants for possible functional effects on gene regulation.

Two variants stood out. The SNP rs11666524, with the A allele as the effect allele, was associated with increased coronary artery disease risk with an odds ratio of 1.21 and a 95 percent confidence interval of 1.02 to 1.45, reaching a p-value of 0.04. The SNP rs2277947, also with the A allele, showed a similar signal, with an odds ratio of 1.22, a confidence interval of 1.01 to 1.46, and a p-value of 0.03. In genetic epidemiology, an odds ratio above 1 means that carriers of the effect allele face modestly elevated odds of disease compared with non-carriers, and the confidence intervals here exclude the null value of 1, though only narrowly, reflecting effects that are real but small, as is typical for common variants in complex disease.

Perhaps the most striking finding emerged when the team stratified the cohort by major cardiovascular risk factors. The strongest genetic effects appeared precisely in people without the usual risk drivers. Among non-smokers, three SNPs, rs10104, rs11666524, and rs2277947, showed significant associations with a p-value of 0.02. Among patients with normal fresh fruit and vegetable intake, rs10104 and rs346158 were significant at p equal to 0.02, while rs11666524 reached p equal to 0.016, rs2277947 p equal to 0.007, and rs8107914 p equal to 0.04. Among patients without obesity, rs10104 was significant at p equal to 0.02, rs11666524 at p equal to 0.01, rs346157 at p equal to 0.004, and rs2277947 at p equal to 0.01. In other words, the genetic contribution of Hero11 becomes most visible when the loud background noise of smoking, poor diet, and obesity is removed, a pattern known as gene-environment interaction in which lifestyle and metabolic factors mask or modify genetic effects.

This interaction pattern is not entirely new to the group. In earlier work, the same laboratory reported that obesity and environmental risk factors significantly modify the association between ischemic stroke and the Hero chaperone C19orf53, and they have documented links between other Hero family members, including C11orf58, or Hero20, C9orf16, also called bulbulin, and SERF2, and the risk of ischemic stroke. The new coronary artery disease findings extend that program from the brain’s vasculature to the heart’s, and they add a mechanistic thread: the study found that C19orf53 SNPs contribute to alterations in coagulation parameters, the laboratory measures of how readily blood clots. That connection matters because the clinical catastrophe in coronary artery disease is usually not the plaque itself but the thrombus that forms when a plaque ruptures, so genes that nudge coagulation could plausibly influence who converts stable atherosclerosis into a heart attack.

The bioinformatic annotation performed by the team points to possible regulatory mechanisms. Tools such as HaploReg and atSNP Search, which map variants onto chromatin states and transcription factor binding sites using data from resources like the GTEx atlas of genetic regulatory effects, allow researchers to ask whether disease-associated SNPs sit in regions that control gene expression. While the abstract does not identify a single causal variant or mechanism, the broader biological context is coherent: mTORC1 signaling regulates the mitochondrial integrated stress response, mTOR inhibition has been proposed as a strategy for stabilizing atherosclerotic plaques, and chaperone proteins such as Hsp27 and the co-chaperone BAG5, whose loss-of-function mutations cause dilated cardiomyopathy, have established roles in cardiovascular pathology. A chaperone gene wired into mTORC1 fits neatly into this landscape.

The study has clear limitations that temper enthusiasm. The association signals are modest, with p-values just under the conventional 0.05 threshold even after permutation correction, and the cohort is confined to individuals of Russian ethnicity from Central Russia, so replication in larger and more diverse populations will be essential before Hero11 can be considered an established coronary risk gene. The authors also received no external funding for the work, and the study was approved by the Ethical Review Committee of Kursk State Medical University, with all participants providing written informed consent. Still, the research was conducted under the Declaration of Helsinki and its statistical framework, using second-generation PLINK tooling, follows standard practice for candidate-gene association studies of this size.

What makes the work compelling is less any single odds ratio than the door it opens. Hero proteins were discovered only recently, and their chaperone-like activity in protecting cells against protein instability and aggregation suggests an entirely underexplored layer of cardiovascular biology, one that connects proteostasis, the cell’s system for managing protein folding, with the inflammatory and metabolic processes that drive atherosclerosis. If larger studies confirm that C19orf53 variants shape coronary risk and coagulation, the finding would join a growing list of hints that the heart’s health depends not only on lipids and blood pressure but also on how faithfully our cells keep their proteins in shape, and it would mark Hero11, a protein obscure enough to be named for its obscurity, as a genuine subject of cardiovascular genetics.

Subject of Research: Association of C19orf53 (Hero11) chaperone gene variants with coronary artery disease risk and coagulation traits

Article Title: The relationship between coronary artery disease and the heat-resistant obscure chaperone Hero11

Article References: Shilenok, V., Kobzeva, K., & Bushueva, O. (2026). The relationship between coronary artery disease and the heat-resistant obscure chaperone Hero11. Molecular Biology Reports, 53(1), Article 1684. https://doi.org/10.1007/s11033-026-12880-x

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12880-x

Keywords: coronary artery disease, C19orf53, Hero11, Hero proteins, molecular chaperones, genetic association study, coagulation, mTORC1, intrinsically disordered proteins, TDP-43, gene-environment interaction, cardiovascular genetics